KRAS and pancreatic neoplasm: Further studies on EVs as therapy delivery system are also needed, as EVs containing siRNA/shRNA against oncogenic KRAS suppressed cancer and increased overall survival in multiple mouse models of pancreatic cancer (Kamerkar et al., 2017).